Mutations that result in deregulated tyrosine kinase signaling often lead to. Receptor tyrosine kinasetargeted cancer therapy mdpi. Type i receptor tyrosine kinases as targets for therapy in. Protein tyrosine phosphatases, new targets for cancer therapy. Tyrosine kinases as targets for cancer therapy presentation discussed in this issue. Chapter 2 protein kinase structure, function, and regulation pages 75117. Biochemical mechanism of action of tyrosine kinase tyrosine kinases are enzymes that selectively phosphorylates tyrosine residue in different substrates. Tyrosine kinases as druggable targets in cancer intechopen. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment. Receptor tyrosine kinases are activated by ligand binding to their extracellular domain. The majority of targets are receptor protein tyrosine kinases rptks, as deregulating mutations of over half of the known rptks have been associated with different human malignancies.
The formation of oncogenic fusion tyrosine kinases ftks resulting from genomic rearrangements. Given the activating role that some ptks play in initiating growth factormediated cellular processes, ptps are usually perceived as the negative regulators of these events and therefore tumor suppressive. Gefitinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor, inducing favorable outcomes in patients with nonsmall cell lung cancers. Tyrosine kinases are a family of proteins that contribute to the development of cancer. Opportunely, many groups have identified favorable molecular targets for inhibition, such as cell surface receptors. Significantly, protein kinases are the second most targeted group of drug targets, after the gproteincoupled. Recent data have shown that a variety of cellular processes essential for bacterial survival and virulence are regulated by the phosphorylation of certain endogenous proteins catalyzed by specific tyrosine kinases.
Role of tyrosine kinase inhibitors in cancer therapy. Drugs targeting the cell cycleregulatory cyclindependent kinase cdk 4 and 6 have been approved for the treatment of hormone receptorpositive breast cancer, and inhibitors targeting other cellcycle cdks are currently in clinical trials. The clinical validation of these firstgeneration tyrosine kinase. Intracellular tyrosine kinases as novel targets for anti. The different steps involved in rtk activation, regulation and synthesis are schematically depicted. Tyrosine kinases are implicated in the pathophysiology of various types of cancers and inhibitors of these enzymes are considered as useful targets in cancer therapy 16. The tyrosine kinase receptors have multidomain extracellular ligands for specific ligand, a signal pass transmembrane hydrophobic helix and tyrosine kinase domain. Akalu department of immunobiology, yale university school of medicine, new haven, ct, usa. Protein tyrosine phosphatases ptp are exciting and novel targets for cancer drug discovery that work in concert with protein tyrosine kinases ptk in controlling cellular homeostasis.
The recent development of smallmolecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Oncogenic fusion tyrosine kinases as molecular targets for. In this article we summarize the rationale for targeting members of the erbb family in. Combining kinase biology with chemistry and pharmacology applications, this book enlists emerging data to drive the discovery of new cancerfighting drugs. Receptor tyrosine kinases as targets for cancer therapy. Tyrosine kinase inhibitors tkis have been developed as targeted molecular therapy approaches for cancer, and the nanoparticlebased tkis delivery strategies are introduced to improve their therapeutic. Treatment of appropriately selected patients with these drugs can alter the natural history of their disease and improve survival. Protein tyrosine kinase ptk deregulation contributes to growth of cancer and many other diseases.
Dasatinib targets additionally the structurally related family of src kinases. Tyrosine kinases as targets for cancer therapy nejm. For these reason therapies directed at these receptors have the potential to be useful anti cancer agents. Incorrect tyrosine kinase function can lead to nonsmall cell lung cancer. View enhanced pdf access article on wiley online library html view. Anticancer drug development has recently taken aim at these receptors. Several studies have identified the protein tyrosine kinases tks as targets for cancer therapy, since enhancement of tk activity has been correlated with cancer and other proliferative diseases. Review article from the new england journal of medicine tyrosine kinases as targets for cancer therapy. The inhibition of growthrelated kinases, especially tyrosine kinases, might therefore provide new therapies for diseases such as cancer. Each step is associated with actual bold face or potential italicized means of inhibition for cancer therapy. The development of smallmolecule tyrosine kinase inhibitors tkis that target the deregulated ptks, such as epidermal growth factor receptor egfr in nonsmallcell lung cancer nsclc and bcrabl in chronic myeloid leukemia cml, has revolutionized disease management.
Nilotinib and dasatinib are also small molecule tyrosine kinase inhibitors, which can be administered orally 4, 5. The major prerequisite to develop such drugs is to understand the. Pdf oncogenic fusion tyrosine kinases as molecular. Unit of cellular signaling, department of biological chemistry, the silverman institute for life sciences, the hebrew university of jerusalem, jerusalem 91904, israel abstract enhanced protein tyrosine kinase ptk activity correlates with the development of cancer and other proliferative diseases.
Deregulated activation of protein tyrosine kinases ptks is a frequent event underlying malignant transformation in many types of cancer. Receptor tyrosine kinases as targets for cancer therapy development. Tyrosine kinases as targets in cancer therapy successes and. This short synopsis is intended to give the reader an introduction to this area of targeted therapy for cancer as a prelude to this special edition of veterinary and comparative oncology. The history and future of targeting cyclindependent kinases in cancer therapy. Receptor tyrosine kinases as targets for anticancer drugs. May 26, 2006 one of the most exciting developments in cancer research in recent years has been the clinical validation of molecularly targeted drugs that inhibit the action of pathogenic tyrosine kinases. Protein phosphorylation plays key roles in many physiological processes and is often deregulated in pathological conditions. Because conventional chemotherapy is not specific for cancer cells leading to toxic side effects there is a need for novel agents with high grade antitumor specificity. Moreover, following rapid advances in the characterization of cellular signaling mechanisms and pathways activated by receptor tyrosine kinases in normal and malignant cells the potential of rtks as selective anticancer targets for therapeutic intervention has been recognized. Dec 27, 2000 the early 1980s, when we began to consider ways to inhibit egf receptor activity, was an exciting time in the receptor field.
Significantly, protein kinases are the second most targeted group of drug targets, after the g. The egfrerbb protein family is comprised of four structurally related kinases. Transcriptionassociated cyclindependent kinases as targets and biomarkers for cancer therapy. Thus, it affects cancer cells more so than normal cells. Targeted therapys specific action differs from traditional chemotherapy, which affects all fast growing cells. Combining kinase biology with chemistry and pharmacology applications, this book enlists emerging data to drive the discovery of new cancer fighting drugs. Searching for targets that allow pharmacological inhibition of cell proliferation in overproliferative states, such as cancer, leads us to finely understand the complex mechanisms orchestrating the perfect co. Pdf in the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients. Many of these kinases are associated with human cancer initiation and progression. An expert guide to targeting protein kinases in cancer therapy research has shown that protein kinases can instigate the formation and spread of cancer when they transmit faulty signals inside cells. Protein tyrosine kinases as targets for cancer and other. Tam receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Mutations in the fmslike tyrosine kinase 3 flt3 receptor in acute myeloid leuke mia aml render this tk active in the absence of ligand5. The tyrosine kinase inhibitors tkis are a class of smallmolecule, orally administered agents with a unique mechanism of action.
The egf receptor family as targets for cancer therapy oncogene. Blocking small molecule inhibitors of kinase domain tkis prevents the phosphorylation of the receptor at tk domain and interferes with cell proliferation, differentiation, migration, and survival and induces cell apoptosis. Protein kinases play a crucial role in signal transduction and also in cellular proliferation, differentiation and various regulatory mechanisms. Particularly, aberrant receptor tyrosine kinase rtk activation is a potential therapeutic target. Targeting protein kinases for cancer therapy david j. Protein tyrosine kinases ptks have become the most promising targets for cancer therapy. Several strategies for targeting tks have been developed, the most successful being monoclonal antibodies and small molecule tyrosine kinase inhibitors.
These advances have led to the investigation of small molecule inhibitors of the erbb family of receptor tyrosine kinases across a broad spectrum of malignancies. Insights into receptor function and new drug development targets pp 167178. Srcfamily kinases sfks are central mediators that involve multiple pathways and can interact with tyrosine kinase receptors, representing a promising target to stop the growth of tumor cells. Tyrosine kinases as targets for cancer therapy new england. Receptor tyrosine kinases as therapeutic targets in. Tyrosine kinases involved in diverse biological processes like.
Finally, and equally as important as the epidemiological and biochemical data, the prevalence of ptks as targets is because of the fact. Over the past several years many advances have been made in our understanding of critical pathways involved in carcinogenesis and tumor growth. Receptor tyrosine kinases and downstream pathways as. Targeting receptor tyrosine kinases by tyrosine kinase inhibitors tkis. Tyrosine kinases as targets for cancer therapy sciencedirect. Tkis are thus an important new class of targeted therapy that interfere with specific cell signaling pathways and thus allow target specific therapy for selected. Tam receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy yemsratch t. To combat this resistance, there is a constant need for antibacterial drugs with new modes of action on therapeutic targets. A series of monoclonal antibodies mabs3 directed against the egf receptor and the closely related erbb2her2neu receptor are currently under evaluation. This paper provides a summary of some specific tyrosine kinases tks and their inhibitors which are used in cancer therapy. Tyrosine kinases, enzymes that catalyze the transfer of phosphate from atp to tyrosine residues in polypeptides, are ubiquitous, numerous, and of considerable clinical interest because they participate in the development of cancer and have become choice targets for therapeutic intervention.
Tyrosine kinases phosphorylate tyrosine residues in an activating mode and are found in important growth factor receptors, such as for ligands from families collectively known as vegf, pdgf and egf, to name a few and in intracellular downstream molecules. Unit of cellular signaling, department of biological chemistry, the silverman institute for life sciences, the hebrew university of jerusalem, jerusalem 91904, israel abstract enhanced protein tyrosine kinase ptk. Protein kinases and phosphatases as therapeutic targets in. Tyrosine kinase signaling is frequently involved in the recruitment of sh2. Tyrosine kinases as ta rgets for cancer therapy presentation discussed in this issue krause ds, van etten ra. For these reason therapies directed at these receptors have the potential to be useful anticancer agents. Seventy percent of tks are receptor tyrosine kinases and these have become key targets for cancer therapy. Because aurora overexpression is associated with malignancy, these kinases have been targeted for cancer therapy. Chapter 4 nonreceptor tyrosine kinases pages 215264. The receptor tyrosine kinases are not only cell surfaces transmembrane. Pdf tyrosine kinases as targets for cancer therapy. Because of this fact, pharmaceutical scientists have targeted kinases for intensive study, and have been working to develop medicinal roadblocks to sever their malignant means of communication. While in normal cell regulation, tk plays a crucial signaling role, but in cancer cells it gets dysregulated. Department of immunobiology, yale university school of medicine, new haven, ct, usa.
Beadbased profiling of tyrosine kinase phosphorylation. Breast carcinomas express high levels of type i tyrosine kinase receptors and their ligands. Receptor tyrosine kinases associated with rhabdomyosarcoma 2. Nanoformulations of small molecule protein tyrosine kinases. Jul 14, 2005 tyrosine kinases as targets for cancer therapy. Tyrosine kinases as targets for cancer therapy semantic scholar. Some have been approved for use in cancer therapy, and several others are in various stages of clinical trials. Dr stanley cohen had accomplished both the identification of egf. Tyrosine kinase, cancer, oncogenic activation, tk inhibitor introduction. Receptor tyrosine kinases have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of. With the deciphering of the human genome project more than 90 tyrosine kinases have been found out. Targeting protein kinases for cancer therapy wiley.
Like imatinib, nilotinib inhibits selectively the tyrosine kinase activity of abl kinases, pdgf receptor and ckit. In recent years, tyrosine kinases tks have been recognized as central players and regulators of cancer cell proliferation, apoptosis, and angiogenesis, and are therefore considered suitable potential targets for anticancer therapies. Tyrosine kinases as targets for cancer therapy presentation discussed in this issue krause ds, van etten ra. These kinases are overexpressed in a number of human cancers, and transfection studies have established auroraa as a bone fide oncogene. In this article we summarize the rationale for targeting members of the. Jul 29, 2004 over the past several years many advances have been made in our understanding of critical pathways involved in carcinogenesis and tumor growth. Tyrosine kinase network signaling in normal physiology and. Tam receptor tyrosine kinases as emerging targets of innate.
Our objective here is to present such kinases as druggable targets for cancer therapy. Another class of cdks, the transcriptionassociated cdks, including cdk7, cdk8, cdk9, cdk12 and cdk, are critical regulators of gene expression. Complete with fullcolor presentations, targeting protein kinases for cancer therapy defines the structural features of protein kinases and examines their cellular functions. The egfrerbb family is a representative target for cancer therapy to which small molecule tyrosine kinase inhibitors tkis and monoclonal antibodies mabs. Protein tyrosine phosphatases ptps catalyse removal, and protein tyrosine kinases ptks the addition of phosphate. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. The role of tyrosine kinases in cancer molecular pathogenesis is immense and recently kinases have come in vogue as potential anticancer drug targets, as a result a couple of anticancer drugs are in the market. Tyrosine phosphorylation can be assessed by phosphoamino acid analysis or, more. Tyrosine kinases as targets in cancer therapy successes. Transcriptionassociated cyclindependent kinases as. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. Molecular mechanisms of acquired resistance to tyrosine. Tyrosine kinase receptors as attractive targets of cancer therapy. Oncogenic fusion proteins, anti cancer therapy, tyrosine kinase, small molecule inhibitors.
Src kinases as therapeutic targets for cancer nature. The egfrerbb family is a representative target for cancer therapy to which small molecule tyrosine kinase inhibitors tkis and monoclonal antibodies mabs are developed, approved and applied. Targeted therapy stops the action of molecules that are key to the growth of cancer cells. Of the 90 unique tyrosine kinase genes identified in the human genome, 58 encode receptor tyrosine kinase proteins. Therapeutic targeting of oncogenic tyrosine phosphatases. The human genome encodes 538 protein kinases that transfer a. The majority of currently available tyrosine kinase inhibitors has provided a new approach for cancer therapy and has the potential for avoiding some of the drawbacks of cytotoxic chemotherapy 22. Transcriptionassociated cyclindependent kinases as targets. Oct 17, 2008 targeted therapy with tyrosine kinase inhibitors. One of the most exciting developments in cancer research in recent years has been the clinical validation of molecularly targeted drugs that inhibit the action of pathogenic tyrosine kinases.
Abstract slides from a journal article and accompanying descriptive summary. Tyrosine kinases are ubiquitous, numerous, and of considerable clinical interest because they participate in the development of cancer and have become choice targets for therapeutic intervention. Pdf receptor tyrosine kinasetargeted cancer therapy. Data from various sources support a role for ptks in transformation and it has long been hypothesized that some ptps will function as tumour suppressor genes. Whether youve loved the book or not, if you give your honest and detailed thoughts then people will find new books that are right for them. In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Other readers will always be interested in your opinion of the books youve read. Role of tyrosine kinase inhibitors in cancer therapy journal of. Our current understanding of how protein kinases and phosphatases orchestrate the phosphorylation changes that control cellular functions has made these enzymes potential drug targets for the treatment of many diseases. Tyrosine kinases as targets for cancer therapy request pdf.
325 1032 80 260 1319 145 591 1416 1060 71 129 485 1429 780 1224 1602 411 512 428 491 746 361 854 1091 1404 5 1525 7 1070 1276 111 272 1401 564 329